Dichloroacetic acid and rapamycin synergistically inhibit tumor progression.
- Author:
Huan CHEN
1
;
Kunming LIANG
2
;
Cong HOU
1
;
Hai-Long PIAO
3
Author Information
- Publication Type:Journal Article
- Keywords: Dichloroacetic acid (DCA); Mammalian target of rapamycin (mTOR); Pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1); Rapamycin
- MeSH: Humans; Sirolimus/pharmacology*; Dichloroacetic Acid/pharmacology*; Pyruvate Dehydrogenase Complex; TOR Serine-Threonine Kinases; Mechanistic Target of Rapamycin Complex 1; Neoplasms/drug therapy*
- From: Journal of Zhejiang University. Science. B 2023;24(5):397-405
- CountryChina
- Language:English
- Abstract: Mammalian target of rapamycin (mTOR) controls cellular anabolism, and mTOR signaling is hyperactive in most cancer cells. As a result, inhibition of mTOR signaling benefits cancer patients. Rapamycin is a US Food and Drug Administration (FDA)-approved drug, a specific mTOR complex 1 (mTORC1) inhibitor, for the treatment of several different types of cancer. However, rapamycin is reported to inhibit cancer growth rather than induce apoptosis. Pyruvate dehydrogenase complex (PDHc) is the gatekeeper for mitochondrial pyruvate oxidation. PDHc inactivation has been observed in a number of cancer cells, and this alteration protects cancer cells from senescence and nicotinamide adenine dinucleotide (NAD+) exhaustion. In this paper, we describe our finding that rapamycin treatment promotes pyruvate dehydrogenase E1 subunit alpha 1 (PDHA1) phosphorylation and leads to PDHc inactivation dependent on mTOR signaling inhibition in cells. This inactivation reduces the sensitivity of cancer cells' response to rapamycin. As a result, rebooting PDHc activity with dichloroacetic acid (DCA), a pyruvate dehydrogenase kinase (PDK) inhibitor, promotes cancer cells' susceptibility to rapamycin treatment in vitro and in vivo.
